This is therefore a contrasting of the profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation in Moleculin Biotech Inc. (NASDAQ:MBRX) and CRISPR Therapeutics AG (NASDAQ:CRSP). The two are both Biotechnology companies that compete with one another.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Moleculin Biotech Inc.||1||0.00||34.76M||-0.51||0.00|
|CRISPR Therapeutics AG||54||0.00||34.37M||-3.74||0.00|
Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Moleculin Biotech Inc. and CRISPR Therapeutics AG.
Table 2 shows us Moleculin Biotech Inc. and CRISPR Therapeutics AG’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Moleculin Biotech Inc.||3,254,072,271.11%||-92.2%||-65.2%|
|CRISPR Therapeutics AG||63,507,021.43%||-50.9%||-39.8%|
Moleculin Biotech Inc. has a Current Ratio of 1.5 and a Quick Ratio of 1.5. Competitively, CRISPR Therapeutics AG’s Current Ratio is 15.8 and has 15.8 Quick Ratio. CRISPR Therapeutics AG’s better ability to pay short and long-term obligations than Moleculin Biotech Inc.
The Ratings and Recommendations for Moleculin Biotech Inc. and CRISPR Therapeutics AG are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Moleculin Biotech Inc.||0||0||1||3.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
Moleculin Biotech Inc. has a 96.08% upside potential and an average target price of $2. Competitively CRISPR Therapeutics AG has an average target price of $66.5, with potential downside of -8.11%. Based on the results given earlier, Moleculin Biotech Inc. is looking more favorable than CRISPR Therapeutics AG, analysts opinion.
Institutional and Insider Ownership
Roughly 17.9% of Moleculin Biotech Inc. shares are owned by institutional investors while 50% of CRISPR Therapeutics AG are owned by institutional investors. Insiders owned 23.73% of Moleculin Biotech Inc. shares. Competitively, 2% are CRISPR Therapeutics AG’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Moleculin Biotech Inc.||-5.22%||-12.1%||-18.05%||-20.44%||-35.72%||4.81%|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Moleculin Biotech Inc. was less bullish than CRISPR Therapeutics AG.
Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. It also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by MoleculinÂ’s pre-clinical drug WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.